SEC Form 4 · accession 0001104659-19-013682
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ivan Bergstein
Officer — Chief Executive Officer · Director
Period of report
Mar 7, 2019
Accepted (ET)
Mar 8, 2019 · 9:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Mar 7, 2019 | S | 6,800 | $11.41 | D | 2,719,351 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1In connection with the vesting of 12,565 shares on March 6, 2019, a total of 6,800 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
- F2Reflects the weighted average sale price. The range of prices for such transaction is $11.19 to $11.54. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Of the 2,719,351 shares, 952,198 shares are restricted stock.